130 patents
Page 7 of 7
Utility
6-5 fused rings as C5a inhibitors
17 Feb 20
Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
Filed: 28 May 18
Utility
Modulators of Chemokine Receptors
5 Feb 20
Xi CHEN, Dean R. DRAGOLI, Junfa FAN, Jaroslaw KALISIAK, Antoni KRASINSKI, Manmohan Reddy LELETI, Venkat MALI, Jeffrey McMAHON, Rajinder SINGH, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG
Filed: 15 May 19
Utility
Heteroaryl sulfonamides and CCR2/CCR9
13 Jan 20
Compounds are provided that act as potent antagonists of the CCR2 receptor.
Solomon Ungashe, Zheng Wei, Arindrajit Basak, Trevor T. Charvat, Wei Chen, Jeff Jin, Jimmie Moore, Yibin Zeng, Sreenivas Punna, Daniel Dairaghi, Derek Hansen, Andrew M. K. Pennell, John J. Wright, Antoni Krasinski, Qiang Wang
Filed: 10 Feb 19
Utility
Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor 9 (CCR9) and anti-α4β7 integrin blocking antibodies
13 Jan 20
Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof.
Karen Ebsworth, Yu Wang, Yibin Zeng, Penglie Zhang, Joanne Tan
Filed: 4 Oct 15
Utility
Processes and intermediates in the preparation of C5aR antagonists
13 Jan 20
Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.
Pingchen Fan, Jaroslaw Kalisiak, Antoni Krasinski, Rebecca M. Lui, Jay Powers, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
Filed: 20 Mar 19
Utility
DOSING AND EFFECT OF C5a ANTAGONIST WITH ANCA-ASSOCIATED VASCULITIS
11 Dec 19
Jun DENG, Petrus BEKKER, Jan HILLSON
Filed: 5 Jun 19
Utility
Soluble C5aR antagonists
25 Nov 19
Pingchen Fan, Antoni Krasinski, Venkat Reddy Mali, Shichang Miao, Sreenivas Punna, Yang Song, Valentino J. Stella, Yibin Zeng, Penglie Zhang
Filed: 18 Mar 19
Utility
Methods of Treating Pancreatic Cancer
20 Nov 19
The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
Petrus Bekker, Shichang Miao, Israel Charo, Tom Schall
Filed: 30 Jul 19
Utility
Substituted tetrahydropyrans as CCR2 modulators
4 Nov 19
Junfa Fan, Jaroslaw Kalisiak, Rebecca M. Lui, Venkat Reddy Mali, Jeffrey P. McMahon, Jay P. Powers, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
Filed: 30 Aug 17
Utility
PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
2 Oct 19
Pingchen FAN, Rebecca M. LUI, Rajinder SINGH, Venkat Reddy MALI, Yibin ZENG, Penglie ZHANG
Filed: 31 Mar 19